According to statistics from Xinzhupai, the number of blue ear vaccine batches issued in 2024 will total 412 million, which is basically the same as in 2023. Boehringer ranks first with more than 60 million batches issued. Jinhe Youben, a subsidiary of Jinhe Bio, which has become popular with blue ear inactivated vaccines, has ranked second for two consecutive years, with nearly 40 million batches issued in 2024.

Public information shows that Jinhe Bio is based on the animal health industry, and has entered the veterinary biological products business field through external mergers and acquisitions, and has a full layout of the veterinary vaccine sector. There are currently 16 products on the market, and more than 20 products under research and application, with broad development space and strong potential.

Among them, the blue ear inactivated vaccine Youlanbao® and blue ear chimeric vaccine Youlantai® launched by Jinhe Bio's subsidiary Jinhe Youben work together perfectly, achieving safety and effectiveness without damaging the immune system, and can also achieve blue ear disease purification. In 2017, after Jinhe Youben launched the blue ear inactivated vaccine Youlanbao® (CH-1a strain), in response to the unsafe use of conventional attenuated viruses, easy to spread, easy to immunosuppress, easy to mutate, and easy to recombine, Jinhe Youben innovatively launched Youlantai®. The two products form the best immune combination and constitute a perfect solution for "live + inactivated" blue ear disease.

In addition, at the end of 2023, the company launched the first animal brucellosis vaccine Youbutai® that meets the ideal standards of the World Health Organization. With the rare Brucellosis missing strain "BA0711", it perfectly solves the limitations of traditional brucellosis vaccines. At the same time, it has achieved comprehensive breakthroughs in human safety, herd immunity, detection and purification, and cattle and sheep universality, and has been recognized by world-class institutions.

Jinhe Bio introduced at the exchange meeting that the company's brucellosis vaccine has successfully won the bid for a large enterprise procurement project, and it is expected to gradually increase in volume in 2025. The company insists on winning with quality. About 80% of its vaccine customers are the top 100 customers in the industry. Large customers have high requirements for vaccine quality, which shows the strong market competitiveness of the company's products.

In addition, the company attaches importance to product research and development and wins the market with products. At present, the company has established two animal vaccine research and development centers in China and abroad. Relying on the American Farmavi R&D Center, it has established a research and development innovation platform with a global vision. The domestic and Southwest Regional Center of the Chinese Academy of Agricultural Sciences will work closely together to continue to bring more innovative products and disease solutions, and continuously consolidate the company's competitiveness.

https://finance.eastmoney.com/a/202502113315593939.html